Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30847966 | 1.00 | PRKCI (0.39) | PRKCICYP3A4TSHRALDH1A1HPGD | |
| SCHEMBL436336 | 0.76 | MEN1 (0.41) | ALDH1A1CMA1PTPN11 | |
| SCHEMBL13836115 | 0.76 | PSMD14 (0.37) | PRKCICMA1PTPN11HTR2AHTR2C | |
| SCHEMBL30109166 | 0.76 | MEN1 (0.41) | ALDH1A1CMA1PTPN11 | |
| SCHEMBL4951560 | 0.76 | CYP3A4 (0.39) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL29989147 | 0.74 | CDK4 (0.41) | PRKCICMA1 | |
| SCHEMBL2178459 | 0.74 | CDK4 (0.43) | PRKCIALDH1A1CMA1PTPN11 | |
| SCHEMBL2052186 | 0.74 | CYP1A2 (0.38) | ALDH1A1HPGDHSD17B10CMA1MAPT | |
| SCHEMBL2625811 | 0.74 | CDK4 (0.41) | PRKCICMA1 | |
| SCHEMBL4953962 | 0.74 | CYP3A4 (0.38) | CYP3A4TSHRALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263760-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-08-21 | — | — | US | disclosed |
| US-12319946-B2 | Methods for producing modified bacteria for production of nitroaromatics | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-06-03 | — | — | US | disclosed |
| CN-118804911-A | Acrylamide compound | NRG治疗有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| US-20240150365-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-3012258-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AND -TRIAZINES AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2585467-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AND -TRIAZINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2016-03-02 | — | — | EP | disclosed |
| WO-2015120320-A1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-1551827-B1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | NOVARTIS AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-20080249111-A1 | Piperdine Derivatives as CCR5 Inhibitors | NOVARTIS AG | 2008-10-09 | — | — | US | disclosed |
| US-7399771-B2 | Piperidine derivatives as CCR5 inhibitors | NOVARTIS AG (CH) | 2008-07-15 | — | — | US | disclosed |
| US-20060004047-A1 | Piperidine derivatives as ccr5 inhibitors | NOVARTIS AG (CH) | 2006-01-05 | — | — | US | disclosed |
| EP-1551827-A1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | Novartis AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004031172-A1 | PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS | NOVARTIS AG (CH) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004047-A1 | Piperidine derivatives as ccr5 inhibitors | CCR5, CCR2, CCR1 | PRKCI 1786/4885CYP3A4 3290/4885TSHR 1041/4885 |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | PRKCI 235/4885CYP3A4 1224/4885TSHR 3346/4885 |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | PRKCI 4139/4885CYP3A4 1243/4885TSHR 966/4885 |
| US-20240150365-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL6B | PRKCI 791/4885CYP3A4 1034/4885TSHR 3380/4885 |
| US-20080249111-A1 | Piperdine Derivatives as CCR5 Inhibitors | CCR5, CCR2, CCR1 | PRKCI 1464/4885CYP3A4 3082/4885TSHR 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.